Buy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion Potential
TipRanks (Mon, 6-May 8:19 PM ET)
Axsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15M
Seeking Alpha News (Mon, 6-May 7:01 AM ET)
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Mon, 6-May 7:00 AM ET)
Axsome Therapeutics Q1 2024 Earnings Preview
Seeking Alpha News (Fri, 3-May 12:54 PM ET)
Notable earnings before Monday's open
Seeking Alpha News (Fri, 3-May 10:39 AM ET)
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Globe Newswire (Wed, 1-May 7:00 AM ET)
Globe Newswire (Tue, 30-Apr 9:00 PM ET)
Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors
PRNewswire (Mon, 29-Apr 4:01 PM ET)
Globe Newswire (Mon, 15-Apr 7:00 AM ET)
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Globe Newswire (Wed, 10-Apr 7:00 AM ET)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics trades on the NASDAQ stock market under the symbol AXSM.
As of May 6, 2024, AXSM stock price climbed to $75.94 with 787,954 million shares trading.
AXSM has a beta of 1.04, meaning it tends to be more sensitive to market movements. AXSM has a correlation of 0.07 to the broad based SPY ETF.
AXSM has a market cap of $3.61 billion. This is considered a Mid Cap stock.
Last quarter Axsome Therapeutics reported $72 million in Revenue and -$.73 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.42.
In the last 3 years, AXSM stock traded as high as $98.40 and as low as $19.38.
The top ETF exchange traded funds that AXSM belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.
AXSM has underperformed the market in the last year with a return of +5.5%, while the SPY ETF gained +28.3%. In the last 3 month period, AXSM fell short of the market, returning -18.2%, while SPY returned +4.8%. However, in the most recent 2 weeks AXSM has outperformed the stock market by returning +11.8%, while SPY returned +4.3%.
AXSM support price is $72.62 and resistance is $76.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXSM stock will trade within this expected range on the day.